The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-01 · 399 (1) · 665-681
DOI: 10.1007/s00210-025-04207-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 16.07.2025. Verfasst von Haiyang Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, RNA-Binding Proteins, Tripartite Motif Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Tripartite motif-containing motif 11 (TRIM11) possesses a pro-tumorigenic properties in non-small cell lung cancer (NSCLC). However, the determinants that drive TRIM11 dysregulation remains to be uncovered. Effect on cell functions was assessed by detecting cell apoptosis, proliferation, viability, ferroptosis, and invasive and migratory capacities. Evaluation of in vivo activity was performed using mouse xenograft studies. Relationship between TRIM11 and METTL3 or IGF2BP1 was predicted by bioinformatics and confirmed by RNA immunoprecipitation experiments or luciferase assays. The regulation of TRIM11 in ACSL4 protein was tested by IP experiment and protein stability analysis. TRIM11 was overexpressed in NSCLC, and its high expression tended to result in poor prognosis and enhanced tumor grade. Functionally, TRIM11 disruption suppresses the malignant progression of NSCLC cells by promoting cancer cell apoptosis and ferroptosis and repressing invasion, proliferation, and migration. Mechanistically, METTL3 enhances m6A modification of TRIM11 mRNA via an IGF2BP1/m6A manner. Inhibition of METTL3 reduced TRIM11 to promote NSCLC cell ferroptosis and suppress malignant progression in vitro, as well as to mediate xenograft growth inhibition in vivo. Additionally, TRIM11 degraded ACSL4 through K63-linked ubiquitination to affect the malignant progression and ferroptosis of NSCLC cells. These findings indicate that the METTL3/IGF2BP1 axis-mediated m6A methylation of TRIM11 mRNA is responsible for NSCLC malignant progression of NSCLC. Our study is instrumental for the development of TRIM11-basic therapies for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Oncology, Cangzhou People's Hospital, Cangzhou, China.
- Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. 46900195@hebmu.edu.cn.
Zitieren
APA
Chen, H., Wang, C., Dai, H., & Shi, J. (2026). The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(1), 665-681. https://doi.org/10.1007/s00210-025-04207-7
Vancouver
Chen H, Wang C, Dai H, Shi J. The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(1):665-681. doi:10.1007/s00210-025-04207-7
BibTeX
@article{Chen2026,
author = {Chen, Haiyang and Wang, Chunmei and Dai, Heyang and Shi, Jian},
title = {The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {1},
pages = {665--681},
doi = {10.1007/s00210-025-04207-7}
}
EUVIMED